TMS for tinnitus is off-label and not supported as a routine treatment. Pooled trials show a short-term reduction in tinnitus distress at about one month that is not seen at six months, and the largest single trial found no benefit over sham. The 2014 American Academy of Otolaryngology–Head and Neck Surgery guideline recommends against TMS for the routine treatment of persistent, bothersome tinnitus.
No TMS device is FDA-cleared for tinnitus. This review sets out what the trials show, why the idea was plausible, and what has better support.
The short version
| Question | Current answer |
|---|---|
| FDA-cleared for tinnitus? | No |
| Short-term effect in pooled trials? | Yes, on distress and loudness ratings at about one month |
| Lasting effect? | Not shown at six months |
| Largest sham-controlled trial? | Negative |
| U.S. guideline position? | Recommends against routine use |
| Usually covered by insurance? | No |
Why researchers tried TMS for tinnitus
Chronic tinnitus is thought to involve the brain as much as the ear. After hearing loss, auditory cortex can become overactive, and networks involved in attention and emotion amplify the sound's intrusiveness. Low-frequency rTMS is generally thought to dampen cortical excitability, so stimulating the temporal cortex at 1 Hz was a logical experiment. The idea is sound neuroscience; the problem is that the clinical results have not held up in larger and longer studies.
What the trials found
The largest trial
A multicenter German trial published in 2017 enrolled 163 people with chronic tinnitus and gave 10 sessions of 1 Hz rTMS (2,000 pulses at 110% of motor threshold) or sham to the left temporal cortex. At the end of treatment, tinnitus questionnaire scores had barely moved in either group, and the difference between active and sham was not significant; depression and quality-of-life measures did not differ either. The authors wrote that the findings "put the efficacy of this rTMS protocol for treatment of chronic tinnitus into question."
The pooled evidence
A 2025 meta-analysis of 16 randomized trials with 1,105 patients found improvement on the Tinnitus Handicap Inventory and on visual-analog ratings at one month, but no positive effect at six months. The 2021 IFCN expert guideline describes the efficacy evidence for tinnitus as relatively poor. The European guideline that grades evidence for rTMS reserved its top rating (Level A, definite efficacy) for depression, neuropathic pain and hand recovery after stroke; tinnitus was not among them.
A benefit that fades within months, after a course of daily sessions, is hard to justify for a chronic condition. It also raises the question of how much of the early effect reflects expectation, which can be strong when the outcome is a subjective rating of an internal sound.
What the guidelines recommend instead
The AAO-HNS guideline focuses on persistent, bothersome tinnitus lasting six months or more in adults, a common problem: the guideline estimates prevalence at 10% to 15% of adults. It recommends a targeted history and examination, a prompt audiologic exam when tinnitus is one-sided, persistent or accompanied by hearing difficulty, a hearing aid evaluation when there is documented hearing loss, and cognitive behavioral therapy. It recommends against TMS, routine medications such as antidepressants, anticonvulsants and anxiolytics for the tinnitus itself, and dietary supplements such as ginkgo, melatonin and zinc.
Cognitive behavioral therapy does not make the sound disappear. It reduces the distress, sleep disruption and attention capture that make tinnitus disabling, and that is what most patients are asking for. The site's CBT page explains the approach.
Start with the right workup
Tinnitus is a symptom, and the first job is to find anything treatable behind it. The AAO-HNS guideline advises against routine head and neck imaging for tinnitus, but makes exceptions when the tinnitus is in one ear only, pulsatile, or accompanied by focal neurologic findings or asymmetric hearing loss. Those features call for an otolaryngologist and audiologist before any discussion of brain stimulation. Medication side effects, jaw and neck problems, and untreated hearing loss are also worth reviewing.
The same evaluation often uncovers insomnia, anxiety or depression, which can account for much of the disability. Treating them can change how intrusive the sound feels, even when the sound itself persists.
If a clinic offers TMS for tinnitus
Some clinics still offer TMS for tinnitus on a self-pay basis. If you are considering it, ask:
- Which sham-controlled trial does the protocol follow, and did that trial show benefit beyond one month?
- Will my hearing be tested before and after, and what hearing protection will be used?
- Do I have hyperacusis, and how will you monitor it?
- What is the plan, and the cost, if the effect fades after a few weeks?
- Is this part of a registered clinical trial?
Clear, specific answers are a minimum. Promises of a cure are a reason to look elsewhere.
Ear-specific risks to weigh
TMS is loud. The coil's click has been measured near the 140 dB limit for impulsive noise, and FDA guidance requires earplugs or similar protection rated at 30 dB of noise reduction for patients and operators. With protection, studies found no change in hearing; one person had a small permanent threshold shift after an earplug slipped out during H-coil stimulation.
- The IFCN guideline warns that TMS may worsen hyperacusis, the painful sensitivity to sound that often accompanies tinnitus.
- Anyone who develops new hearing loss, tinnitus or ear fullness after TMS should be referred for an auditory evaluation.
- Tinnitus appears among the symptoms in voluntary FDA adverse-event reports for TMS devices, though such reports are unverified and cannot give an incidence rate.
The broader safety profile is covered in TMS safety and seizure risk.
Coverage
Tinnitus is not a covered use in the insurer policies reviewed for this guide. EmblemHealth's technology database, for example, marks TMS for tinnitus as not covered across its commercial, Medicare and Medicaid plans. The EmblemHealth and GHI coverage guide explains its TMS policy for depression.
If you have tinnitus and depression
Persistent tinnitus and depression can occur together, and each can make the other harder to live with. Depression is a separate, cleared indication for TMS, and having tinnitus does not by itself rule TMS out. It does call for a conversation about hearing protection, a baseline hearing test, and a plan if the tinnitus gets louder during the course. In that situation, the depression evidence, not the tinnitus evidence, drives the decision. Comparable reasoning applies to other off-label uses reviewed in this hub, such as migraine, where a dedicated TMS device is cleared, and chronic pain, where neuropathic pain reached a higher evidence level than tinnitus.
For a wider view of TMS and its cleared uses, see the TMS guide and the TMS overview.
Frequently asked questions
Does TMS cure tinnitus?
No. Some trials show a short-term drop in tinnitus distress, but pooled data show no lasting benefit at six months, and the largest sham-controlled trial found no difference from sham.
Can TMS make tinnitus worse?
It can in some cases. The coil is loud and hearing protection is required, and expert guidance notes that TMS may worsen sound sensitivity (hyperacusis). New or louder tinnitus after TMS warrants a hearing evaluation.
What treatment for tinnitus has the best evidence?
U.S. otolaryngology guidelines recommend cognitive behavioral therapy for persistent, bothersome tinnitus and a hearing aid evaluation when hearing loss is present.
Can I have TMS for depression if I have tinnitus?
Tinnitus does not automatically rule it out. Discuss hearing protection, consider a baseline hearing test, and agree on what to do if the tinnitus changes during treatment.
Is TMS for tinnitus covered by insurance?
Generally no. EmblemHealth, for example, lists it as not covered.
Sources
- Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation (rTMS) Systems. U.S. FDA, 2011. fda.gov
- Safety and recommendations for TMS use in healthy subjects and patient populations, with updates on training, ethical and regulatory issues: Expert Guidelines. Clinical Neurophysiology, 2021. europepmc.org
- Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). Clinical Neurophysiology, 2020. europepmc.org
- Efficacy of repetitive transcranial magnetic stimulation for subjective chronic tinnitus: a randomized controlled trial meta-analysis. Frontiers in Neuroscience, 2025. europepmc.org
- Postmarketing Safety of Transcranial Magnetic Stimulation: A 10-Year MAUDE Database Analysis of Adverse Events and Technological Advancements. J Clin Psychiatry, 2026. pubmed.ncbi.nlm.nih.gov
- EmblemHealth Medical Technology Database. EmblemHealth, 2025. emblemhealth.com
- Clinical practice guideline: tinnitus. Otolaryngology-Head and Neck Surgery (AAO-HNS), 2014. europepmc.org
- 1-Hz rTMS in the treatment of tinnitus: A sham-controlled, randomized multicenter trial. Brain Stimulation, 2017. europepmc.org
- FDA 510(k) K182976 (SpringTMS). U.S. FDA, 2019. accessdata.fda.gov
Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.
The information provided on this blog is for educational and informational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
A Message From Dr. Lewis If you’ve been struggling with depression or anxiety, I want you to know something important:
The Conversation That Surprised Me A few years ago, I had a patient named Greg who’d been on escitalopram (Lexapro)
You’re Not Meant to Go Through Life Alone In our increasingly connected yet often isolating world, you might sometimes feel